136 related articles for article (PubMed ID: 38497299)
1. PI3K and tankyrase inhibitors as therapeutic targets in colorectal cancer.
Yakkala PA; Naaz F; Shafi S; Kamal A
Expert Opin Ther Targets; 2024 Mar; 28(3):159-177. PubMed ID: 38497299
[TBL] [Abstract][Full Text] [Related]
2. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
Arqués O; Chicote I; Puig I; Tenbaum SP; Argilés G; Dienstmann R; Fernández N; Caratù G; Matito J; Silberschmidt D; Rodon J; Landolfi S; Prat A; Espín E; Charco R; Nuciforo P; Vivancos A; Shao W; Tabernero J; Palmer HG
Clin Cancer Res; 2016 Feb; 22(3):644-56. PubMed ID: 26224873
[TBL] [Abstract][Full Text] [Related]
3. TANKYRASE Inhibition Enhances the Antiproliferative Effect of PI3K and EGFR Inhibition, Mutually Affecting β-CATENIN and AKT Signaling in Colorectal Cancer.
Solberg NT; Waaler J; Lund K; Mygland L; Olsen PA; Krauss S
Mol Cancer Res; 2018 Mar; 16(3):543-553. PubMed ID: 29222171
[TBL] [Abstract][Full Text] [Related]
4. mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer.
Mashima T; Taneda Y; Jang MK; Mizutani A; Muramatsu Y; Yoshida H; Sato A; Tanaka N; Sugimoto Y; Seimiya H
Oncotarget; 2017 Jul; 8(29):47902-47915. PubMed ID: 28615517
[TBL] [Abstract][Full Text] [Related]
5. Tankyrase inhibitors as antitumor agents: a patent update (2013 - 2020).
Mehta CC; Bhatt HG
Expert Opin Ther Pat; 2021 Jul; 31(7):645-661. PubMed ID: 33567917
[TBL] [Abstract][Full Text] [Related]
6. Are Wnt/β-Catenin and PI3K/AKT/mTORC1 Distinct Pathways in Colorectal Cancer?
Prossomariti A; Piazzi G; Alquati C; Ricciardiello L
Cell Mol Gastroenterol Hepatol; 2020; 10(3):491-506. PubMed ID: 32334125
[TBL] [Abstract][Full Text] [Related]
7. Regulation of Wnt/β-catenin signalling by tankyrase-dependent poly(ADP-ribosyl)ation and scaffolding.
Mariotti L; Pollock K; Guettler S
Br J Pharmacol; 2017 Dec; 174(24):4611-4636. PubMed ID: 28910490
[TBL] [Abstract][Full Text] [Related]
8. A novel tankyrase small-molecule inhibitor suppresses APC mutation-driven colorectal tumor growth.
Lau T; Chan E; Callow M; Waaler J; Boggs J; Blake RA; Magnuson S; Sambrone A; Schutten M; Firestein R; Machon O; Korinek V; Choo E; Diaz D; Merchant M; Polakis P; Holsworth DD; Krauss S; Costa M
Cancer Res; 2013 May; 73(10):3132-44. PubMed ID: 23539443
[TBL] [Abstract][Full Text] [Related]
9. Tankyrase Inhibitors Stimulate the Ability of Tankyrases to Bind Axin and Drive Assembly of β-Catenin Degradation-Competent Axin Puncta.
Martino-Echarri E; Brocardo MG; Mills KM; Henderson BR
PLoS One; 2016; 11(3):e0150484. PubMed ID: 26930278
[TBL] [Abstract][Full Text] [Related]
10. Targeting Tankyrase to Fight WNT-dependent Tumours.
Thorvaldsen TE
Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):81-88. PubMed ID: 28371398
[TBL] [Abstract][Full Text] [Related]
11.
Tanaka N; Mashima T; Mizutani A; Sato A; Aoyama A; Gong B; Yoshida H; Muramatsu Y; Nakata K; Matsuura M; Katayama R; Nagayama S; Fujita N; Sugimoto Y; Seimiya H
Mol Cancer Ther; 2017 Apr; 16(4):752-762. PubMed ID: 28179481
[TBL] [Abstract][Full Text] [Related]
12. The Anti-Tumor Activity of Succinyl Macrolactin A Is Mediated through the β-Catenin Destruction Complex via the Suppression of Tankyrase and PI3K/Akt.
Regmi SC; Park SY; Kim SJ; Banskota S; Shah S; Kim DH; Kim JA
PLoS One; 2015; 10(11):e0141753. PubMed ID: 26544726
[TBL] [Abstract][Full Text] [Related]
13. The Discovery and Characterization of K-756, a Novel Wnt/β-Catenin Pathway Inhibitor Targeting Tankyrase.
Okada-Iwasaki R; Takahashi Y; Watanabe Y; Ishida H; Saito J; Nakai R; Asai A
Mol Cancer Ther; 2016 Jul; 15(7):1525-34. PubMed ID: 27196752
[TBL] [Abstract][Full Text] [Related]
14. Targeting Wnt-driven cancers: Discovery of novel tankyrase inhibitors.
Ferri M; Liscio P; Carotti A; Asciutti S; Sardella R; Macchiarulo A; Camaioni E
Eur J Med Chem; 2017 Dec; 142():506-522. PubMed ID: 29107427
[TBL] [Abstract][Full Text] [Related]
15. BET protein-dependent E2F pathway activity confers bell-shaped type resistance to tankyrase inhibitors in APC-mutated colorectal cancer.
Morino S; Mashima T; Shirai F; Nagayama S; Katayama R; Seimiya H
Cancer Lett; 2024 Mar; 584():216632. PubMed ID: 38216082
[TBL] [Abstract][Full Text] [Related]
16. Tankyrase Inhibitors Target Colorectal Cancer Stem Cells via AXIN-Dependent Downregulation of c-KIT Tyrosine Kinase.
Jang MK; Mashima T; Seimiya H
Mol Cancer Ther; 2020 Mar; 19(3):765-776. PubMed ID: 31907221
[TBL] [Abstract][Full Text] [Related]
17. Structure, Dynamics, and Functionality of Tankyrase Inhibitor-Induced Degradasomes.
Thorvaldsen TE; Pedersen NM; Wenzel EM; Schultz SW; Brech A; Liestøl K; Waaler J; Krauss S; Stenmark H
Mol Cancer Res; 2015 Nov; 13(11):1487-501. PubMed ID: 26124443
[TBL] [Abstract][Full Text] [Related]
18. Tankyrase inhibitors attenuate WNT/β-catenin signaling and inhibit growth of hepatocellular carcinoma cells.
Ma L; Wang X; Jia T; Wei W; Chua MS; So S
Oncotarget; 2015 Sep; 6(28):25390-401. PubMed ID: 26246473
[TBL] [Abstract][Full Text] [Related]
19. RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model.
Mizutani A; Yashiroda Y; Muramatsu Y; Yoshida H; Chikada T; Tsumura T; Okue M; Shirai F; Fukami T; Yoshida M; Seimiya H
Cancer Sci; 2018 Dec; 109(12):4003-4014. PubMed ID: 30238564
[TBL] [Abstract][Full Text] [Related]
20. Distinct Colorectal Cancer-Associated APC Mutations Dictate Response to Tankyrase Inhibition.
Schatoff EM; Goswami S; Zafra MP; Foronda M; Shusterman M; Leach BI; Katti A; Diaz BJ; Dow LE
Cancer Discov; 2019 Oct; 9(10):1358-1371. PubMed ID: 31337618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
